
---
title: '质疑在中临床试验 美拒批准2项中国抗癌药'
categories: 
 - 新媒体
 - 快媒体
 - 首页更新
headimg: 'https://www.kuai.media/news/2022/05/03/static/image/kuai/external-link.gif'
author: 快媒体
comments: false
date: 2022-05-03 00:43:57
thumbnail: 'https://www.kuai.media/news/2022/05/03/static/image/kuai/external-link.gif'
---

<div>   
<a href="https://www.kuai.media/go.php?aid=384509" target="_blank" role="link" data-focusable="true" class="sum" rel=" noopener noreferrer">

<strong>摘要</strong>: The @FDA has rejected yet another Chinese-developed cancer medication, this time from @hutchmed, and asking for a new trial that's more representative of the U.S. patient population. https://t.co/RomV1kZlVTmdash; FiercePharma (@FiercePharma) May 2, 2022〔自由财经综合报导〕美国食品药品监督管理局（FDA）拒绝批准两种主要在中国进行测试的抗癌药物。FDA对由美国Coherus BioSciences Inc和中国合作伙伴上海君实生物医药科技（ Shanghai Junshi Biosciences Co Ltd ）的治疗鼻咽癌（一种头颈癌）的疗法发出拒绝批准回函，另外也拒绝批准Hutchmed针对晚期神经内分泌肿瘤 （NET） 上市的多激酶抑制剂的申请。Hut ... <span class="more"><img width="35" src="https://www.kuai.media/news/2022/05/03/static/image/kuai/external-link.gif" referrerpolicy="no-referrer">点击阅读全文 @ltn.com.tw</span>
</a>


  
</div>
            